
About Novo Nordisk
Novo Nordisk is a publicly listed company based in Bags Sword (Denmark) founded in 1923. Drugs for diabetes, obesity, hemophilia, and hormone therapy are manufactured. It operates on a Direct-to-Consumer (D2C) and Professional Services model. Novo Nordisk has raised $145 thousand across 9 funding rounds from investors including European Union and IFU. The company has 61,878 employees. Novo Nordisk has completed 13 acquisitions, including Akero Therapeutics, Biocorp and Calibrium. Its chief executive, as recorded, is Lars Fruergaard Jorgensen. Its website novonordisk.com draws about 638 thousand monthly visits. Its Indian entity Novo Nordisk Service Centre (India) Private Limited reported revenue of ₹1,921 Cr. Novo Nordisk offers products and services including Ozempic, Wegovy, and Cagrilintide. Its focus areas include Pharmaceuticals and Biotechnology.
Company details
Novo Nordisk is focused on the development and distribution of pharmaceutical products targeting chronic conditions such as diabetes and obesity. Solutions are provided in various therapeutic areas with an emphasis on innovative treatments. The company operates within the healthcare sector, prioritizing science and technology to address unmet medical needs. Sustainable business practices are integrated into operations, alongside partnerships and a commitment to responsible sourcing. Global procurement strategies are employed to ensure quality and efficiency in supply chains.
- Indian entity revenue₹1,921 Cr
FY 2025 · +38% YoY
- Indian entity net profit₹220 Cr
FY 2025 · 11% margin
- Indian entity EBITDA₹386 Cr
FY 2025 · 20% margin
- Total Equity Funding$145K (USD)
in 9 rounds
- Latest Funding Round$173.74K (USD), Grant
Mar 2022
- InvestorsEuropean Union
& 1 more
- Employee Count61,878
- Investments & AcquisitionsAkero Therapeutics
& 12 more
Associated legal entities of Novo Nordisk
Novo Nordisk operates through Novo Nordisk Service Centre (India) Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Novo Nordisk Service Centre (India) Private Limited CIN U74990KA2011PTC057129 | Active | 15 Feb 2011 | Bengaluru, Karnataka | ₹1,921 Cr | 3,480 | 4 | View details |
Products & Services of Novo Nordisk
Novo Nordisk offers a comprehensive portfolio of products and services, including Ozempic, Wegovy, and Cagrilintide.
Ozempic is used for reducing cardiovascular risks effectively.
Wegovy is prescribed for weight loss management purposes.
Cagrilintide is developed for advanced obesity treatment solutions.
Apps and channels of Novo Nordisk
its YouTube channel Novo Nordisk has 3.52K subscribers and 30 videos.
Videos from Novo Nordisk
The most watched videos on Novo Nordisk's YouTube channel, Novo Nordisk (3.52K subscribers). Click a video to play it here.
More on Novo Nordisk.
Funding Insights of Novo Nordisk
Novo Nordisk has successfully raised a total of $145K across 9 strategic funding rounds. The most recent funding activity was a Grant round of $173.74 thousand completed in March 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $145,000
- Total Rounds 9
- Last Round Grant — $173,745
- First Round $145,000
(Jun 1984)
- Investors Count 2
All 9 funding rounds of Novo Nordisk with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2022 | $173,745 | Grant | – | – | |
| Jan 2021 | $364,871 | Grant | – | – | |
| Jan 2020 | Grant | – | – | ||
| Jan 2018 | $348,415 | Grant | – | – | |
| Sep 2016 | $649,668 | Grant | – | – | |
| Jan 2015 | $350,669 | Grant | – | – | |
| Sep 2012 | $10,027 | Grant | – | – | |
| Jun 2011 | $1.74M | Post-IPO | – | – | |
| Jun 1984 | $145,000 | Private Equity Round | – | IFU | – |
2 investors in total: 2 institutional.
Investors in Novo Nordisk
Novo Nordisk has secured backing from 2 investors, including institutional and venture fund investors. Prominent investors backing the company include European Union and IFU.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity investment firm | 1967 | ifu.dk | Copenhagen, Denmark | |
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium |
Investor details for Novo Nordisk
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Novo Nordisk Service Centre (India) Private Limited (Novo Nordisk)
Novo Nordisk Service Centre (India) Private Limited is the primary company behind Novo Nordisk. The board of Novo Nordisk Service Centre (India) Private Limited currently have 4 directors; the longest-serving is Soren Thor Jensen, appointed in 2012. 13 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Soren Thor Jensen DIN 05173608 | Director | 09 Mar 2012 | 14 yrs 8 mo | Novo Nordisk Service Centre (India) Private Limited |
| Lene Hylling Axelsson DIN 08470408 | Director | 16 Oct 2019 | 7 yrs 1 mo | Novo Nordisk Service Centre (India) Private Limited |
| Vikrant Shrotriya DIN 08635146 | Director | 11 Nov 2021 | 5 yrs | Novo Nordisk Service Centre (India) Private Limited |
| John Christopher Dawber DIN 09812822 | Managing Director | 29 Sep 2023 | 3 yrs 1 mo | Novo Nordisk Service Centre (India) Private Limited |
People of Novo Nordisk
1137 people are tracked at Novo Nordisk (546 in leadership, 9 in board & advisors, 582 in team); the tracked headcount is 61,878.
| Name | Role | Group |
|---|---|---|
Lars Fruergaard Jorgensen | CEO & President | Leadership |
Anne-Kristine Prag Steinitz | Corporate Vice President Strategic Scientific Communication, Global Medical Affairs | Leadership |
Cecilie Heerdegen Jepsen | Head Of Translational Medicine | Leadership |
Malgorzata Wnuk | Strategic Finance & Project Director | Leadership |
Allegra Kaufman | Executive Director, Clinical Development Strategy | Leadership |
Greg Horikoshi | Associate Director Commercial Execution | Leadership |
Claudia Laven | Vice President | Obesity Care | Leadership |
David Scott | Director, Legal, Ethics, Compliance And Quality | Leadership |
Sofie Inari Castella | Global Director, Scientific Publications | Leadership |
Rasmus Sonne Henniker Heaton | Sr. Business & Project Partner | Leadership |
Ghita Bahbouhi | Supply Chain Analytics Partner | Leadership |
Teresa Sophie K. | Director, IME & Medical Association Partnerships | Leadership |
Ulrik Ullum | Senior Director | Leadership |
Katy Long | Snr Dir, HR Business Partner, International Operations | Leadership |
Victor Vazquez | Talent Acquisition Partner Americas (latam, USA & Canada) | Leadership |
Al Willis | Senior Director - Deployment Strategy & Sales Innovation | Leadership |
Morten Engelund | Corporate Vice President, Total Rewards And Mobility | Leadership |
Briana Dunn | Associate Director Search And Evaluation | Leadership |
Jacob Sten Petersen | Corporate Vice President, Stem Cell R&D | Leadership |
Konstantinos Ratsikas | Senior Supply Chain Partner | Leadership |
1117 more people are available in the full profile.
Complete people profiles for Novo Nordisk
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Novo Nordisk
Novo Nordisk is a publicly listed company on the OMXCOP with ticker symbol NOVO_B in Denmark, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date07 Jan 2000
- Listed onNASDAQ: NOVO B
- Listed entityNovo Nordisk A/S Class B
- Exchange sectorHealth technology
- ISINDK0062498333
- Share price253.60 DKK (-1.19% on the day) · 2026-10-14
- Market capitalisation1,137,691,183,097.00 DKK
- Price to earnings9.7
- EPS (diluted, trailing year)26.19 DKK
- Dividend yield4.56%
- Volume (last session)278,302
Financials of Novo Nordisk
Figures of Novo Nordisk Service Centre (India) Private Limited, the primary company behind Novo Nordisk, for FY 2025. Revenue was ₹1,921 Cr (+38% year on year). Net profit was ₹220 Cr (11% margin). EBITDA was ₹386 Cr (20% margin). Revenue has grown at a compounded annual rate of +39% over three years and +28% over five years.
- ₹1,921 CrRevenue · FY 2025 · +38% YoY
- ₹220 CrNet profit · 11% margin
- ₹386 CrEBITDA · 20% margin
- ₹4.01 CrPaid-up capital
- 3,480Employees (provident fund records)
- +39%Revenue CAGR, 3 years
- +28%Revenue CAGR, 5 years
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 309.06B DKK | 102.43B DKK | 149.69B DKK |
| 2024 | 290.40B DKK | 100.99B DKK | 147.95B DKK |
| 2023 | 232.26B DKK | 83.68B DKK | 111.38B DKK |
| 2022 | 176.95B DKK | 55.52B DKK | 81.02B DKK |
| 2021 | 140.80B DKK | 47.76B DKK | 64.32B DKK |
Balance sheet, profit and loss, cash flow and ratios of Novo Nordisk Service Centre (India) Private Limited are on its company page.
Detailed financial statements for Novo Nordisk
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Novo Nordisk
Novo Nordisk has strategically engaged in corporate development activities, having acquired 13 companies. Notable acquisitions include Akero Therapeutics, Biocorp and Calibrium.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Small molecule therapeutics for metabolic disorders are developed. | akerotx.com | San Francisco, United States | 2017 | Oct 2025 | $4.7B | |
Non-coding RNA therapeutics are developed for cardiovascular disease treatment. | cardior.de | Hannover, Germany | 2016 | Mar 2024 | •••• | |
Multiple courses and degrees are offered across diversified academic streams. | ku.dk | Copenhagen, Denmark | 1479 | Sep 2023 | •••• | |
Novel therapeutics for metabolic diseases and obesity are developed. | embarkbiotech.com | Copenhagen, Denmark | 2017 | Aug 2023 | •••• | |
Drug delivery systems and medical devices are developed and manufactured. | biocorpsys.com | Issoire, France | 2004 | Jun 2023 | $164.87M | |
Developer of therapeutic solutions for multiple health purposes | formatherapeutics.com | Watertown, United States | 2007 | Sep 2022 | $1.1B | |
Drugs are developed using RNA interference technology platform. | dicerna.com | Lexington, United States | 2007 | Nov 2021 | $3.3B | |
Technology for delivery of therapeutic molecules | emisphere.com | Roseland, United States | 1986 | Nov 2020 | $1.8B | |
Cardiovascular therapies are developed using functional genomics approaches. | corvidiatx.com | Waltham, United States | 2015 | Jun 2020 | $725M | |
Biosensor platforms for carbohydrates are developed using photonics and optoelectronics. | ziylo.com | Bristol, United Kingdom | 2014 | Aug 2018 | $800M |
Complete acquisition details for Novo Nordisk
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Novo Nordisk
14 dated milestones of Novo Nordisk across 102 years, from founding to its latest funding, stage changes and deals.
- Founded Novo Nordisk is founded.
- Funding First funding round of $145K.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires Ziylo.
- Acquisition Acquires Corvidia Therapeutics.
- Acquisition Acquires Emisphere.
- Acquisition Acquires Dicerna Pharmaceuticals.
- Funding Latest funding round, Grant, of $174K.
- Acquisition Acquires Forma Therapeutics.
- Acquisition Acquires Biocorp.
- Acquisition Acquires Embark Biotech.
- Acquisition Acquires University of Copenhagen.
- Acquisition Acquires Cardior Pharmaceuticals.
- Acquisition Acquires Akero Therapeutics.
Web traffic of Novo Nordisk
The website of Novo Nordisk (novonordisk.com) receives about 637.8K visits a month and ranks #83,485 among all websites worldwide, #2,383 in Health.
- Monthly visits637.8K
▼ 0.5% vs previous month
- Unique visitors299.1K
per month
- Global rank#83,485
among all websites
- Category rank#2,383
Health · Health
- Bounce rate48%
- Pages per visit2.4
- Average visit1 min 12 sec
- DevicesDesktop 46% · Mobile 54%
Websites whose visitors overlap most with Novo Nordisk. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| lilly.com | 100% | 4.9M | #13,252 | View details | |
| novonordisk-us.com | 96% | 89K | #469,241 | View details | |
| gsk.com | 84% | 1.3M | #56,834 | View details | |
| novartis.com | 77% | 948.8K | #58,822 | View details | |
| abbott.com | 77% | 917.2K | #65,577 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 40 similar websites and full traffic analytics for Novo Nordisk
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 40 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Novo Nordisk
Complete news archive for Novo Nordisk
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Novo Nordisk
Novo Nordisk was founded in 1923 and raised its 1st funding round 61 years after it was founded.
Novo Nordisk is headquartered in Bags Sword, Denmark.
Lars Fruergaard Jorgensen is the CEO of Novo Nordisk, as recorded in our data.
Novo Nordisk is a funded company, having raised a total of $145K across 9 funding rounds to date. The company's 1st funding round was a Private Equity Round of $145K, raised on Jun 1984.
Novo Nordisk has 61,878 employees.
The primary company behind Novo Nordisk, Novo Nordisk Service Centre (India) Private Limited, reported revenue of ₹1,921 Cr for FY 2025, up 38% year on year.
Novo Nordisk is focused on the development and distribution of pharmaceutical products targeting chronic conditions such as diabetes and obesity. Solutions are provided in various therapeutic areas with an emphasis on innovative treatments. The company operates within the healthcare sector, prioritizing science and technology to address unmet medical needs. Sustainable business practices are integrated into operations, alongside partnerships and a commitment to responsible sourcing. Global procurement strategies are employed to ensure quality and efficiency in supply chains.
Novo Nordisk offers Ozempic, Wegovy, and Cagrilintide.
Yes, Novo Nordisk is publicly traded on OMXCOP under the ticker symbol NOVO_B.
Novo Nordisk has made 13 acquisitions, including Akero Therapeutics, Biocorp, and Calibrium.
Novo Nordisk has 2 investors. Key investors include European Union, and IFU.
Novo Nordisk operates through Novo Nordisk Service Centre (India) Private Limited.
